PAX5 and diffuse large B-cell lymphoma: In a previous Japanese study, 34 (12.5%) of 273 DLBCL patients were PD-L1+ (≥ 30% cells positive for PD-L1 and PAX5 by IHC), which were associated with the non-GCB subtype and had worse overall survival (OS) compared with PD-L1− patients47.